Abstract
T cell differentiation into distinct T helper (Th) subpopulations is crucial in governing acquired immune responses as well as some inflammatory and autoimmune disorders. This study investigated potential of the novel neutral binuclear ruthenium(II) complexes 1–8 with general formula [{RuCl2(η6-p-cym)}2μ-(N∩N)] (N∩N = bis(nicotinate)- and bis(iso-nicotinate)-polyethylene glycol esters; (3-py)COO(CH2CH2O) n CO(3-py) and (4-py)COO(CH2CH2O) n CO(4-py); n = 1–4), as well as [RuCl2(η6-p-cym)(nic)] (R1, nic = nicotinate) and [RuCl2(η6-p-cym)(inic)] (R2, inic = isonicotinate) as an immunomodulatory agents capable to direct Th cell differentiation. From all investigated complexes, [{RuCl2(η6-p-cym)}2μ-{(3-py)COO(CH2CH2O)4CO(3-py)}] (4) was selected for further study because it did not affect splenocyte viability (in concentration up to 50 μM), but significantly reduced secretion of representative Th1 cytokine, IFN-γ induced by T cell mitogen. Besides IFN-γ, 4 inhibited dose dependently expression and production of representative Th17 cytokine, IL-17, in these cells. Otherwise, the production of anti-inflammatory cytokines IL-4 and IL-10 was upregulated. Also, 4 significantly increased CD4+CD25+FoxP3+ Treg cell frequency in the activated splenocytes. Moreover, ConA-induced expression of Th1 transcription factors, T-bet and STAT1, as well as of Th17-related protein STAT3 was attenuated upon exposure to 4, while the expression of Th2-related transcription factor GATA3 remained stable. In conclusion, ruthenium(II) complex 4 modulates immune system cell functions in vitro by inhibiting T cell differentiation towards pathogenic Th1/Th17 phenotype and inducing a regulatory phenotype characterized by IL-10 and IL-4 production, which may provide novel therapeutic opportunities for immune-inflammatory and/or autoimmune disorders.
Similar content being viewed by others
References
Kopf-Maier P (1994) Eur J Clin Pharmacol 47:1–16
Nazarov AA, Risse J, Ang WH, Schmitt F, Zava O, Ruggi A, Groessl M, Scopelitti R, Juillerat-Jeanneret L, Hartinger CG, Dyson PJ (2012) Inorg Chem 51:3633–3639
Pandrala M, Li F, Feterl M, Myliana J, Warner JM, Wallace L, Keene FR, Collins JG (2013) Dalton Trans 42:4686–4689
Inuguez E, Sanchez A, Vasquez MA, Martinez A, Olivas J, Sattler A, Sanchez-Delgado RA, Maldonado RA (2013) J Biol Inorg Chem 18:779–790
Glans L, Ehnbom A, de Kock C, Martínez A, Estrada J, Smith PJ, Haukka M, Sánchez-Delgado RA, Nordlander E (2012) Dalton Trans 41:2764–2773
Kreuser ED, Keppler BK, Berdel WE, Piest A, Thiel E (1992) Semin Oncol 19:73–81
Ludwig G, Kaluđerović GN, Bette M, Block M, Paschke R, Steinborn D (2012) J Inorg Biochem 113:77–82
Ludwig G, Kaluđerović GN, Rueffer T, Bette M, Korb M, Block M, Paschke R, Lang H, Steinborn D (2013) Dalton Trans 42:3771–3774
Anitha P, Chitrapriya N, Jang YJ, Viswanathamurthi P (2013) J Photochem Photobiol B 129:17–26
Jiang GB, Xie YY, Lin GJ, Huang HL, Liang YH, Liu ZJ (2013) J Photochem Photobiol B 129:48–56
Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B (2005) Cancer Lett 226:115–121
Brabec V, Nováková O (2006) Drug Resist Update 9:111–122
Wang F, Bella J, Parkinson JA, Sadler PJ (2005) J Biol Inorg Chem 10:147–155
Sava G, Bergamo A (1999) Anticancer Res 19:1117–1124
Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S (1996) Int J Cancer 68:60–66
Pacor S, Zorzet S, Cocchietto M, Bacac M, Vadori M, Turrin C, Gava B, Castellarin A, Sava G (2004) J Pharmacol Exp Ther 310:737–744
Dwyer DS, Gordon K, Jones B (1995) Int J Immunopharmacol 17:931–940
Bastos CM, Gordon KA, Ocain TD (1998) Bioorg Med Chem Lett 8:147–150
Newcomb JR, Rivnay B, Bastos CM, Ocain TD, Gordon K, Gregory P, Turci SM, Sterne KA, Jesson M, Krieger J, Jenson JC, Jones B (2003) Inflamm Res 52:263–271
Bacac M, Vadori M, Sava G, Pacor S (2004) Cancer Immunol Immunother 53:1101–1110
Antonarakis ES, Emadi A (2010) Cancer Chemother Pharmacol 66:1–9
Eichhorn T, Hey-Hawkins E, Maksimović-Ivanić D, Mojić M, Schmidt J, Mijatović S, Schmidt H, Kaluđerović GN (2015) Appl Organomet Chem 29:20–25
Silveira-Lacerda EdP, Vilanova-Costa CA, Pereira FdC, Hamaguchi A, Pavanin LA, Goulart LR, Homsi-Brandenburgo MI, Soares AM, dos Santos WB, Nomizo A (2010) Biol Trace Elem Res 133:270–283
Parkin J, Cohen B (2001) Lancet 357:1777–1789
Zhu J, Yamane H, Paul WE (2010) Annu Rev Immunol 28:445–489
Zhou L, Chong MM, Littman DR (2009) Immunity 30:646–655
Jiang S, Dong C (2013) Immunol Rev 252:5–11
Zheng W, Flavell RA (1997) Cell 89:587–961
Awasthi A, Kuchroo VK (2009) Int Immunol 21:489–498
Chen Z, Laurence A, O’Shea JJ (2007) Semin Immunol 19:400–814
Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004) J Immunol 172:5213–5221
Campbell DJ, Koch MA (2011) Nat Rev Immunol 11:119–130
Dinarello CA (2010) Cell 140:935–950
Saksida T, Stosic-Grujicic S, Timotijevic G, Sandler S, Stojanovic I (2012) Immunol Cell Biol 90:688–698
Kolls JK, Linden A (2004) Immunity 21:467–476
Billiau A, Matthys P (2009) Cytokine Growth Factor Rev 20:97–113
Onishi RM, Gaffen SL (2010) Immunology 129:311–321
Magombedze G, Reddy PB, Eda S, Ganusov VV (2013) Front Physiol 4:206
Betelli E, Korn T, Kuchroo VK (2007) Curr Opin Immunol 19:1–6
Vahedi G, Poholek AC, Hand TW, Laurence A, Kanno Y, O’Shea JJ, Hirahara K (2013) Immunol Rev 252:24–40
Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun HW, Kanno Y, Powrie F, O’Shea JJ (2010) Immunity 32:605–615
Tanaka S, Suto A, Iwamoto T, Kashiwakuma D, Kagami S, Suzuki K, Takatori H, Tamachi T, Hirose K, Onodera A, Suzuki J, Ohara O, Yamashita M, Nakayama T, Nakajima H (2014) J Exp Med 211:1857–1874
Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau F, Yu H, Pardoll DM, Drake CG (2007) J Immunol 179:4313–4317
Moore KW, De Waal Malefyt R, Coffman RL, O’Garra A (2001) Annu Rev Immunol 19:683–765
Romagnani S (2006) Clin Exp Allergy 36:1357–1366
Kaplan MH, Schindler U, Smiley ST, Grusby MJ (1996) Immunity 4:313–319
Rincόn M, Dérijard B, Chow C-W, Davis RJ, Flavell RA (1997) Genes Funct 1:51–68
Acknowledgments
This work was supported by Ministry of Education, Science and Technological Development, Republic of Serbia (Grant No. 173013).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Momcilovic, M., Eichhorn, T., Blazevski, J. et al. In vitro effects of binuclear (η 6-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen. J Biol Inorg Chem 20, 575–583 (2015). https://doi.org/10.1007/s00775-015-1242-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-015-1242-x